“…Innovations in shunt valve technology have promised benefits in reducing SVS, but outcomes data are mixed. The use of programable valves and antisiphoning devices may have a role in modifying the risk of SVS, 5 but these devices cost $3320 each, limiting their global application. 1 Patients with an extensive history of shunt failures, as rates of shunt failure in the first year are 40%, may benefit more from ETV or the MTV approach suggested by the authors.…”